What does CUSIP 29286M105 represent in this 13F holders report?

CUSIP 29286M105 is the security identifier for ENGN - enGene Therapeutics Inc. - Common Shares used to aggregate holder disclosures.

How many institutions held ENGN - enGene Therapeutics Inc. - Common Shares in Q3 2025?

37 institutional investors reported ENGN - enGene Therapeutics Inc. - Common Shares for Q3 2025. Use the holders table for investor-level position and value details.

enGene Therapeutics Inc. - Common Shares (ENGN)

CUSIP: 29286M105

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Shares
Shares outstanding: 67,203,014
Total 13F shares: 40,858,497
Share change: +448,012
Total reported value: $279,063,473
Price per share: $6.83
Number of holders: 37
Value change: +$5,402,489
Number of buys: 14
Number of sells: 14

Quarterly Holders Quick Answers

What is CUSIP 29286M105?
CUSIP 29286M105 identifies ENGN - enGene Therapeutics Inc. - Common Shares in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 29286M105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ENGN - enGene Therapeutics Inc. - Common Shares (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Forbion Growth Opportunities Fund I Cooperatief U.A.	3/4/5	10%+ Owner	— class O/S missing	6,798,362	$60,505,422	—	30 Oct 2024	3/4/5
Fonds de solidarite des travailleurs et des travailleuses du Quebec	3/4/5 13D/G	10%+ Owner	4.5% from 13D/G	3,036,153	$45,542,295	—	18 Apr 2024	3/4/5 13D/G
Lumira Capital Investment Management Inc.	3/4/5	10%+ Owner	— class O/S missing	3,849,299	$38,492,990	—	20 Feb 2024	3/4/5
FCPM III SERVICES B.V.	13F	Company	— mixed-class rows	12,510,709 mixed-class rows	$37,422,603	—	30 Jun 2025	13F
VR Adviser, LLC	13F	Company	7.5%	5,046,414	$18,368,947	—	30 Jun 2025	13F
Kynam Capital Management, LP	13F	Company	7.4%	4,994,090	$18,178,488	—	30 Jun 2025	13F
Deep Track Capital, LP	13F	Company	6.8%	4,557,575	$16,589,573	—	30 Jun 2025	13F
Blue Owl Capital Holdings LP	13F	Company	— mixed-class rows	3,764,206 mixed-class rows	$13,599,908	—	30 Jun 2025	13F
Cormorant Asset Management, LP	13F	Company	3.5%	2,323,595	$8,457,886	—	30 Jun 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	— mixed-class rows	2,006,008 mixed-class rows	$7,301,023	—	30 Jun 2025	13F
Adage Capital Management, L.P.	13D/G	—	3%	1,528,768	$6,115,072	$0	31 Dec 2024	13D/G
Point72 Asset Management, L.P.	13F	Company	1.8%	1,208,299	$4,398,208	—	30 Jun 2025	13F
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	1.8%	945,402	$3,781,608	-$8,424,148	27 Jan 2025	13D/G
FRANKLIN RESOURCES INC	13F	Company	1.5%	1,038,000	$3,778,320	—	30 Jun 2025	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	1.5%	1,000,000	$3,640,000	—	30 Jun 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	1.3%	899,086	$3,272,673	—	30 Jun 2025	13F
SR ONE CAPITAL MANAGEMENT, LP	13F	Company	1.1%	747,750	$2,721,810	—	30 Jun 2025	13F
ORBIMED ADVISORS LLC	13F	Company	1%	677,977	$2,467,836	—	30 Jun 2025	13F
Omega Fund Management, LLC	13F	Company	— mixed-class rows	847,859 mixed-class rows	$2,188,895	—	30 Jun 2025	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.75%	504,409	$1,836,049	—	30 Jun 2025	13F
Vestal Point Capital, LP	13F	Company	0.55%	370,000	$1,346,800	—	30 Jun 2025	13F
MORGAN STANLEY	13F	Company	0.52%	352,768	$1,284,076	—	30 Jun 2025	13F
MARSHALL WACE, LLP	13F	Company	0.51%	343,928	$1,251,898	—	30 Jun 2025	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.26%	174,570	$635,433	—	30 Jun 2025	13F
BVF INC/IL	13F	Company	— class O/S missing	945,402	$586,149	—	30 Jun 2025	13F
Affinity Asset Advisors, LLC	13F	Company	0.11%	77,000	$280,280	—	30 Jun 2025	13F
Saba Capital Management, L.P.	13F	Company	— class O/S missing	178,334	$146,234	—	30 Jun 2025	13F
NORTHERN TRUST CORP	13F	Company	0.05%	33,026	$120,215	—	30 Jun 2025	13F
Calamos Advisors LLC	13F	Company	— class O/S missing	150,000	$118,305	—	30 Jun 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.04%	29,018	$105,625	—	30 Jun 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.04%	27,787	$101,145	—	30 Jun 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.03%	23,043	$83,877	—	30 Jun 2025	13F
D. E. Shaw & Co., Inc.	13F	Company	— class O/S missing	104,622	$70,055	—	30 Jun 2025	13F
Philip Astley-Sparke	3/4/5	Director	— mixed-class rows	65,000 mixed-class rows	$65,000	—	08 Jul 2025	3/4/5
Pale Fire Capital SE	13F	Company	0.03%	17,254	$62,805	—	30 Jun 2025	13F
TORONTO DOMINION BANK	13F	Company	— mixed-class rows	14,638 mixed-class rows	$52,998	—	30 Jun 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.02%	13,030	$47,429	—	30 Jun 2025	13F
TENOR CAPITAL MANAGEMENT Co., L.P.	13F	Company	— class O/S missing	55,243	$45,299	—	30 Jun 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.02%	11,400	$41,496	—	30 Jun 2025	13F
Paloma Partners Management Co	13F	Company	0.02%	10,319	$37,561	—	30 Jun 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.01%	7,915	$29,000	—	30 Jun 2025	13F
WHITEBOX ADVISORS LLC	13F	Company	— class O/S missing	31,000	$25,420	—	30 Jun 2025	13F
WOLVERINE ASSET MANAGEMENT LLC	13F	Company	0.01%	6,361	$23,154	—	30 Jun 2025	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	— class O/S missing	23,570	$18,590	—	30 Jun 2025	13F
UBS Group AG	13F	Company	— class O/S missing	19,664	$16,124	—	30 Jun 2025	13F
CSS LLC/IL	13F	Company	— class O/S missing	16,895	$13,854	—	30 Jun 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	3,199	$11,644	—	30 Jun 2025	13F
MAI Capital Management	13F	Company	0%	2,925	$10,647	—	30 Jun 2025	13F
RAYMOND JAMES FINANCIAL INC	13F	Company	0%	2,068	$7,528	—	30 Jun 2025	13F
NBC SECURITIES, INC.	13F	Company	0%	380	$1,000	—	30 Jun 2025	13F

Institutional Holders of enGene Therapeutics Inc. - Common Shares (ENGN) as of Q3 2025

As of 30 Sep 2025, enGene Therapeutics Inc. - Common Shares (ENGN) was held by 37 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 40,858,497 shares. The largest 10 holders included FCPM III SERVICES B.V., VR ADVISER, LLC, Kynam Capital Management, LP, Blue Owl Capital Holdings LP, Cormorant Asset Management, LP, BRAIDWELL LP, Deep Track Capital, LP, PERCEPTIVE ADVISORS LLC, Point72 Asset Management, L.P., and Frazier Life Sciences Management, L.P.. This page lists 37 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

Q3 2025 holders

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.